CHRNA10

Across TCGA pan-cancer cohorts, CHRNA10 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHRNA10 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CHRNA10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRNA10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

SKCM, UCEC, and LIHC are the cancer types where CHRNA10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.107	0.761	<.001	20	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.030	14	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
STAD	DFS	Median	All	0.184	0.554	.029	9	view →
BLCA	DFS	Median	II,III,IV	1.000	0.329	.038	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.237	0.709	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHRNA10–SKCM (DFS)

Open the SKCM breakdown →